About Webinar

Lung cancer is one of the commonest malignancies in our country with a high mortality rate. There has been a significant improvement in the outcome in advanced lung cancer in the last 2 decades. This has been possible due to unravelling and a deeper knowledge of the biomarkers in lung cancer. Epidermal growth factor receptor inhibitors are the protype of the first targeted therapy used in lung cancer. Indeed, targeted therapy and immunotherapy have revolutionized the treatment landscape in lung cancer. Aggressive local therapy has also led to better local control mainly in the setting of brain metastases. This CME focusses on the recent advances in the management of EGFR mutated lung cancer. The contents will be useful for practicing oncologists and physicians treating lung cancer.

Program Director

Dr. Sourav Kumar Mishra,
Associate Professor

Department of medical oncology
AIIMS, Bhubaneswar

Faculty

Dr. Srigopal Mohanty,
Consultant Medical Oncologist,

HCG Panda Cancer Hospital,
Cuttack, India

Faculty

Dr. Sthiti Das,
Consultant Radiation Oncologist,

APOLLO Cancer Center,
Bhubaneswar, India

Registration

Lung Cancer Agenda

Time (IST) Program Faculty
07.00 PM - 07.10 PM
(5 Minutes, 5 Questions)
Quiz Dr. Srigopal Mohanty; Consultant medical oncologist, HCG Panda Cancer Hospital, Cuttack
7:10 PM – 7:40 PM
(30 Minutes)
Recent advances in the management of EGFR mutated advanced lung cancer Dr. Sourav Kumar Mishra; Associate Professor Department of medical oncology AIIMS, Bhubaneswar
7:40 PM – 8:00 PM
(20 Minutes)
Local therapy in the management of EGFR mutated lung cancer with brain and bone metastases Dr. Sthiti Das; Consultant radiation oncologist, APOLLO cancer center, Bhubaneswar
Question and answer sessions
Concluding remarks